**PRODUCT INFORMATION**

**Flecainide (acetate)**
*Item No. 20388*

**CAS Registry No.**  54143-56-5  
**Formal Name:**  N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-benzamide, monoacetate  
**MF:**  C_{17}H_{20}F_{6}N_{2}O_{3} • C_{2}H_{4}O_{2}  
**FW:**  474.4  
**Purity:**  ≥98%  
**UV/Vis.:**  λ_{max} = 261 nm  
**Supplied as:**  A crystalline solid  
**Storage:**  -20°C  
**Stability:**  ≥4 years  

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

**Laboratory Procedures**

Flecainide (acetate) is supplied as a crystalline solid. A stock solution may be made by dissolving the flecainide (acetate) in the solvent of choice, which should be purged with an inert gas. Flecainide (acetate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of flecainide (acetate) in ethanol is approximately 10 mg/ml and approximately 15 mg/ml in DMSO and DMF. Flecainide (acetate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, flecainide (acetate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Flecainide (acetate) has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

**Description**

Flecainide is an inhibitor of cardiac late sodium current (I\textsubscript{Na}; IC\textsubscript{50} = 3.4 µM) and delayed-rectifier potassium current (I\textsubscript{Kr}; IC\textsubscript{50} = 1.5 µM).\textsuperscript{1-3} Formulations containing flecainide have been used in the treatment of arrhythmias and sodium-dependent calcium overload associated with myocardial ischemia and heart failure.

**References**